Rise and Fall of an Anti-MUC1 Specific Antibody
2011

Development of a Human Anti-MUC1 Antibody for Breast Cancer Treatment

Sample size: 6 publication 10 minutes Evidence: moderate

Author Information

Author(s): Thie Holger, Toleikis Lars, Li Jiandong, von Wasielewski Reinhard, Bastert Gunther, Schirrmann Thomas, Esteves Isabel Tourais, Behrens Christian K., Fournes Bénédict, Fournier Nathalie, de Romeuf Christophe, Hust Michael, Dübel Stefan

Primary Institution: Technische Universität Braunschweig, Institut für Biochemie und Biotechnologie, Braunschweig, Germany

Hypothesis

Can a human anti-MUC1 scFv antibody be effectively generated and tested for therapeutic use in breast cancer?

Conclusion

The study successfully generated a highly specific anti-MUC1 antibody, but its therapeutic efficacy was limited by the target biology.

Supporting Evidence

  • The anti-MUC1 scFv reacted with tumor cells in over 80% of breast cancer tissue samples.
  • The affinity of the scFv was increased up to 500-fold through mutagenesis and phage display.
  • The antibody showed low reactivity with non-tumor tissues.
  • Despite high specificity, the therapeutic success was limited by the target biology.

Takeaway

Scientists created a special antibody to fight breast cancer, but it didn't work as well as they hoped because of how the cancer cells behave.

Methodology

The study involved isolating a human scFv antibody from breast cancer patients, followed by affinity maturation and testing in vitro and in vivo.

Limitations

The antibody showed low stability and affinity, which limited its effectiveness in therapeutic applications.

Participant Demographics

Breast cancer patients who were vaccinated with MUC1 glycopeptides.

Digital Object Identifier (DOI)

10.1371/journal.pone.0015921

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication